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Highlights 
• After 5 years follow-up, almost one-fifth (19%) of participants developed MS 
• Increased serum levels of iron protect against MS in women but not in men 
• Increased serum levels of transferrin favour the development of MS 
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ABSTRACT 
Background and aims: Whether iron metabolism affects metabolic syndrome (METS) is debated. We 
assessed the association between several markers of iron metabolism and incidence of MS. 
Methods and results: Data from 3,271 participants (1,870 women, 51.3±10.4 years), free of MS at 
baseline and followed for 5.5 years. The association of serum iron, ferritin and transferrin with 
incident METS was assessed separately by gender. Incidence of METS was 22.6% in men and 16.5% in 
women (p<0.001). After multivariate adjustment, a positive association was found between 
transferrin and incident METS in men: Odds ratio (OR) and (95% confidence interval) for the fourth 
relative to the first quartile 1.55 (1.04-2.31), p for trend=0.03, while no association was found for iron 
OR=0.81 (0.53-1.24), p for trend=0.33 and ferritin OR=1.30 (0.88-1.92), p for trend=0.018. In women, 
a negative association was found between iron and incident METS: OR for the fourth relative to the 
first quartile 0.51 (0.33-0.80), p for trend<0.03; the association between transferrin and incident 
METS was borderline significant: OR=1.45 (0.97-2.17), p for trend=0.07 and no association was found 
for ferritin: OR=1.11 (0.76-1.63), p for trend=0.58. 
Conclusion: transferrin, not ferritin, is independently associated with an increased risk of incident 
METS; the protective effect of iron in women should be further explored. 
 
Keywords: iron; ferritin; transferrin; metabolic syndrome; incidence; prospective study 
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INTRODUCTION 
Several studies have shown that moderately elevated serum ferritin levels are associated 
with an increased prevalence of metabolic syndrome (METS) [1-3] or some of its components, such 
as high blood pressure [4]. On another hand, several studies have shown the beneficial effects of 
phlebotomy on impaired insulin sensitivity and insulin secretion [5], hypertryglyceridemia [6], high 
blood pressure [7], impaired fasting glucose and HbA1c [7]. Although most studies associating iron 
metabolism and METS have used a cross-sectional setting [1-3], two recent prospective studies have 
shown that baseline elevated serum ferritin [8, 9] and transferrin [9] levels were associated with 
higher incidence of METS. Still, some studies relied on a relatively small number of participants [9], 
were limited to a single marker of iron metabolism [8] or to a limited component of METS [10]. 
Thus, we aimed at assessing the association between several markers of iron metabolism and 
the 5.5-year incidence of METS in a Swiss population-based sample. 
METHODS 
Sampling 
The Cohorte Lausannoise (CoLaus) study is a population-based study, aimed to assess the 
epidemiology of cardiovascular risk factors and diseases in the population of Lausanne, Switzerland. 
The CoLaus study has been approved by the Ethics Committee of the Canton Vaud and all 
participants provided their written informed consent before participating. The sampling procedure of 
the CoLaus study has been described previously [11]. Briefly, recruitment began in June 2003 and 
ended in May 2006. The complete list of the Lausanne inhabitants aged 35–75 years (n=56,694) was 
provided by the population registry of the city and a simple, nonstratified random sample of 35% was 
drawn [11]. Inclusion criteria were applied: 1) written informed consent; 2) age 35–75 years; 3) 
willingness to take part in the examination and to have a blood sample drawn. Participation rate was 
41% and 6,733 participants (3,544 women and 3,189 men) were recruited at baseline. A first 5-year 
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follow-up combining a comprehensive CVRF and CVD assessment with a psychiatric exam was 
conducted between 2009 and 2012. To maximize follow up, letters and brochures were sent to 
participants at six-month intervals. Six months before the intended follow-up interview, a letter 
describing the goals of the follow-up, the requirements for participation and the importance of their 
contribution to long-term efforts in disease prevention was sent to the participants. Prior to the 
follow-up interview, participants received the detailed information letter and consent forms. For 
more details of the follow-up procedure, please consult [12]. 
Personal and clinical data 
Similarly to the baseline evaluation [11], the follow-up examination was conducted at the 
CHUV in Lausanne and included an interview, a physical exam, blood and urine collections and a list 
of questionnaires on self-report dietary habits, physical activity, sleep patterns and disorders [12]. 
Smoking was categorized into never, former (irrespective of the delay since quitting smoking) and 
current. Alcohol consumption was categorized into none, 1-13 and ≥14 drinks/week. 
Women were asked if they were menopaused or not, and if they were taking any hormonal 
treatment (contraception or hormone replacement therapy). Personal history of and current 
treatment for hypercholesterolemia, hypertension or diabetes were also asked. Participants were 
asked to bring all their medicines and information on the use of doctor- and self-prescribed drugs 
was collected, together with their main indications. Iron supplementation was obtained from the 
participant’s intake of medicines and/or vitamin/mineral supplements. 
Body weight and height were measured in light indoor clothes and without shoes. Body 
weight was measured in kilograms to the nearest 100g using a Seca® scale, which was calibrated 
regularly. Height was measured to the nearest 5 mm using a Seca® height gauge. Body Mass Index 
(BMI) was calculated as weight (kg) divided by the square of the height (m). Overweight was defined 
as BMI ≥25 kg/m2 and <30 kg/m2, and obesity by a BMI ≥30 kg/m2. Waist was measured with a non-
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stretchable tape over the unclothed abdomen at the narrowest point between the lowest rib and the 
iliac crest. Two measures were made and the mean used for analyses. 
Blood pressure was measured on the left arm, with an appropriately sized cuff, after at least 
10 minute rest in the seated position, using an Omron® HEM-907 automated oscillometric 
sphygmomanometer. Three readings were taken and the average of the last two was used to 
compute systolic (SBP) and diastolic (DBP) blood pressure. 
Biological data 
Blood was taken in the fasting state and analyses were performed at the Central Chemistry 
Laboratory and the Laboratory of Endocrinology of the CHUV. Vials used for blood collection were 
suitable for iron measurements, and the clinical laboratory was submitted to an external quality 
auditing. The following analytical procedures (with maximum inter and intra-batch CVs) were used at 
baseline and follow-up: HDL-cholesterol by CHOD-PAP + PEG + cyclodextrin (3.6%-0.9%); triglycerides 
by GPO-PAP (2.9%-1.5%) and glucose by glucose dehydrogenase (2.1%-1.0%). High sensitivity C-
reactive protein (hsCRP) was assessed by immunoassay (HS latex, 4.6%-1.3%) and log-transformed 
for statistical analyses. Baseline alanine aminotransferase (ALAT) and aspartate aminotransferase 
(ASAT) were assessed by the International Federation of Clinical Chemistry (IFCC) method at 37°C 
(5.6%-0.7% for ALAT and 3.6%-1.8% for ASAT). Altered hepatic markers were defined as hsCRP≥20 
and/or [ALAT>80 (men) or >62 U/L (women)] and/or [ASAT>74 (men) or >62 U/L (women)] [2] and 
used as a binary (yes/no) variable. No imagiology data was available for the adequate identification 
of fatty liver disease. 
Iron was assessed by colorimetric method (ferrozine, BioSystems; 2.9%-2.2%); ferritin by 
immunoturbidimetric method (Tina-quant 4th generation, Roche Diagnostics, Switzerland; 9.9%-
7.2%); transferrin by immunoassay with a maximum intra-assay (1.8%-1.0%).  
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Metabolic syndrome and its components 
Metabolic syndrome (METS) was defined as the presence of three or more of the following 
criteria set forth by the National Cholesterol Education Program Adult Panel III guidelines [13]: 1) 
Elevated blood pressure (≥130/85 mmHg), 2) abdominal obesity (waist circumference >102 cm in 
men and >88 cm in women), 3) low HDL-cholesterol (<40mg/dL in men and <50mg/dL in women), 4) 
elevated serum triglycerides (>150mg/dL), and 5) elevated fasting plasma glucose (>110mg/dL). 
Statistical analysis 
The following exclusion criteria were applied 1) missing data for the variables of interest 
(markers of iron metabolism or METS components); 2) possible hemochromatosis, based on a 
transferrin saturation >50%; 3) presence of METS at baseline and 4) not attending the follow-up visit. 
Due to the skewed distribution of the markers of iron metabolism, and similar to a preceding 
study [8], a categorization into gender-specific quartiles was performed, with a further stratification 
according to menopausal status in women. Pairwise correlations between markers of iron 
metabolism were assessed separately for each gender using Spearman nonparametric correlation 
coefficient. 
Statistical analyses were performed using Stata version 13.0 (Stata Corp, College Station, 
Texas, USA). All analyses were stratified by gender; in women, a further stratification on menopausal 
status was applied as performed by others [9]. Descriptive results were expressed as number of 
participants (percentage) or as average±standard deviation. The associations between incident MS 
and quartiles of markers of iron metabolism were assessed using chi-square and multivariate logistic 
regression. The results of the multivariate analysis were expressed as Odds ratio (OR) and 95% 
confidence interval (CI). Two models were tested: 1) using all quartiles as categories and 2) 
comparing the fourth to the first quartile. For the first model, a test for trend was applied using the 
contrast q. function of Stata. A sensitivity analysis adjusting only for age and categorizing participants 
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into low (<4th quartile) ferritin/low transferrin; high (4th quartile) ferritin/low transferrin; low 
ferritin/high transferrin and high ferritin/high transferrin as performed in a previous study [9] was 
also conducted. Statistical significance was assessed for p<0.05. 
RESULTS 
Characteristics of participants 
Among the initial 6,733 participants at baseline, 3,462 (51%) were excluded according to the 
criteria defined previously (Figure 1). Thus, the final analytical sample consisted of 3,271 individuals, 
the main characteristics of which according to gender and menopausal status are summarized in 
supplementary table 1. 
Associations between markers of iron metabolism and incident metabolic syndrome 
The distribution of the different quartiles of markers of iron metabolism according to 
incidence of METS is summarized in table 1. After stratifying on gender, a positive association 
between serum ferritin and transferrin and METS was found in men and women. 
The results of the multivariate analysis of the associations between quartiles of markers of 
iron metabolism and incident METS are summarized in table 2. In men, only the positive association 
between increasing quartiles of transferrin retained significance (table 2). In women, the negative 
association between increasing quartiles of serum iron and incidence of METS was maintained while 
the positive association between increasing quartiles of transferrin was borderline significant (table 
2). 
Further stratification on menopausal status among women showed that the associations 
between markers of iron metabolism and incidence of METS were similar between pre- and 
postmenopausal women (supplementary tables 2 and 3), and no significant interaction with 
menopausal status was found (p=0.66, p=0.07 and p=0.78 for iron, ferritin and transferrin, 
respectively).Finally, adjusting for age only showed an increase in the risk of developing METS which 
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was maximal for high ferritin/high transferrin levels in men and postmenopausal women, but not in 
premenopausal women (supplementary figure 1). 
DISCUSSION 
To our knowledge, this is one of the largest prospective studies assessing the associations 
between markers of iron metabolism and incident METS. Our results suggest that increased serum 
transferrin levels are positively associated with the development of METS while increased iron levels 
might be negatively associated with the development of METS in women in women. 
Increased transferrin levels were positively associated with incident METS, a finding in 
agreement with a previous study [9]. Conversely, and contrary to the same study [9], no association 
was found between ferritin and incident METS after multivariate analysis. A possible explanation is 
the fact that in the previous study only adjustment for age was performed, while in the current study 
adjustment for age and for other risk factors for METS was performed. As ferritin levels are 
significantly correlated with BMI, the observed association between ferritin and METS might actually 
be due to BMI rather than to ferritin itself. Indeed, several studies have shown a negative association 
between ferritin and serum adiponectin [5, 14, 15], a hormone whose levels are reduced in obesity 
and with multiple metabolic roles, namely the increase in insulin sensitivity [10, 16]. Interestingly, 
adjusting for age only led to findings similar to those of the previous study, i.e. an increase in the risk 
of developing METS which was maximal for high ferritin/high transferrin levels in men and 
postmenopausal women, but not in premenopausal women (supplementary figure 1). Hence, our 
results suggest that transferrin might be an independent predictor of METS, while the effect of 
ferritin might be confounded by other risk factors for METS. 
Finally, a negative association between serum iron levels and incident METS was found in 
women only, and this association appeared to be independent of the menopausal status.  
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Physiopathology 
Two main hypotheses have been put forward to explain the association between markers of 
iron metabolism and METS. The first one is that METS leads to increased inflammatory status, which 
in turn leads to changes in iron homeostasis [17]. [18]According to this hypothesis, iron would be 
considered a marker rather than a cause of METS. 
The second hypothesis would be that moderately elevated transferrin could lead to METS 
through multiple complex mechanisms [10, 15, 19]. The first mechanism implies the excessive 
formation of reactive oxygen species (ROS) from peroxide reactions combined with the inhibition of 
antioxidative defenses such as Superoxide Dismutase 2 [10]. As pancreatic beta cells have a low 
expression of antioxidants such as catalase and SOD2, they are particularly sensitive to ROS, leading 
to impaired insulin secretion. Hepatic cells store most of the body ferritin and display a high 
mitochondrial activity, making them likely targets for ROS. Indeed, one third of patients with METS 
present with dysmetabolic iron overload syndrome, a condition characterized by altered regulation 
of iron transport, hepatic steatosis, insulin resistance, and subclinical inflammation (for a review, see 
[20]). Thus, transferrin-related increase in ROS levels could lead to an up regulation of 
gluconeogenesis and to impaired lipid metabolism, two components of METS [10, 19, 21]. The action 
of ROS on circulating insulin could increase insulin resistance [10], while vessel damage due to ROS 
could induce both high blood pressure and atherosclerosis [22] 
Overall, it remains to be clarified whether METS leads to higher levels of markers of iron 
metabolism or whether higher levels of markers of iron metabolism lead to METS. It should be noted 
that these two mechanisms are not mutually exclusive and likely correspond to a continuous, self-
sustaining circle between iron metabolism and METS. 
Differences by gender or menopausal status 
The negative association between serum iron levels with incident METS was no longer 
significant in men but remained statistically significant in women, although no significant interaction 
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with gender was observed. It is possible that some associations might have been missed due to the 
gender stratification, which led to smaller sample sizes and thus reduced statistical power. Another 
possibility is that the association between serum iron levels and incident METS observed in women 
was due to chance, i.e. a false positive association. Noteworthy, the incidence of METS was lower in 
women than in men (16.5% vs. 22.6%, respectively, p<0.001), mainly due to the very low incidence of 
METS among premenopaused women (9.9%) while the incidence of METS among post menopausal 
women was comparable to men (23.3%). Still, the association between iron levels and incident METS 
remained after stratification on menopausal status, while the association between transferrin and 
incident METS almost reached statistical significance in postmenopausal women (OR for the last vs. 
the first quartile: p=0.052). Overall, our results suggest that, similar to diabetes [23], increased 
transferrin levels are a risk factor for the development of METS in both genders, while the protective 
effect of increased serum iron levels in women should be further explored. 
No interaction was found for menopausal status regarding ferritin, a finding in contradiction 
with the results of a previous Korean study, which reported a significant association between ferritin 
levels and METS in postmenopausal but not in premenopausal women [24]. One possible explanation 
is differences in postmenopausal metabolism according to ethnicity [25]. Still, when categorizing 
ferritin data into tertiles, the odds ratios for women in the third tertile compared to women in the 
first tertile were 1.41 (0.93–2.13) for postmenopausal and 0.60 (0.33 – 1.08) for premenopausal 
women. Interestingly, the P-value for interaction by menopause status was 0.026, a value almost 
similar to the one reported by the Korean group (0.023). The odds ratio for postmenopausal women 
found in our study was also close to the one reported by the Korean group [1.62 (1.04–2.51)]. Thus, 
our results suggest that there might be differences in the association between ferritin levels and 
METS incidence according to menopausal status, but our sample size might be too small to detect 
significant associations within each group (pre and postmenopausal). 
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Possible therapeutic measures against metabolic syndrome 
Treatment of iron levels exceeding the upper normal physiological limit has been shown to 
favourably reduce several components of METS such as insulin resistance, LDL/HDL ratio, high blood 
pressure or hyperglycaemia [7, 26]. The results of our study further suggest that a decrease in 
transferrin levels within the physiological range could also decrease the risk of developing METS in 
men and postmenopausal women. 
Strengths and limitations 
This study has several strengths. First, it assessed several markers of iron metabolism, while 
other studies focused solely on ferritin [8, 27] or ferritin and transferrin [9]. Second, it used the same 
analytical methodology (centiles) as other studies [8], thus enabling comparison of findings. 
This study has also several limitations. First, a sizable fraction of the initial cohort was 
excluded, thus precluding representativeness. Still, it was necessary in order to have a cohort devoid 
of METS. Second, the follow-up period was rather short (5.5 years), leading to a small number of 
incident METS cases and reducing statistical power. Hence, it is possible that testing for interaction 
terms was somewhat hampered. The ongoing follow-up of the CoLaus cohort (completion due mid 
2017) will allow the collection of a larger number of METS cases and a better testing of the potential 
interactions between gender and the different markers of iron metabolism. Finally, it was not 
possible to take into account dietary intake of iron, as no dietary assessment was performed at 
baseline. 
We conclude that increased transferrin levels are associated with an increased risk of METS, 
while the protective effect of iron in women should be further explored. 
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FIGURE LEGEND 
Figure 1: selection procedure of participants. 
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TABLES 
Table 1: Association between quartiles of markers of iron metabolism and incident metabolic syndrome, stratified by gender, CoLaus study. 
  First Second Third Fourth p-value 
Men       
Iron No METS 292 (26.9) 287 (26.5) 294 (27.1) 211 (19.5) 0.68 
 Incident METS 88 (27.8) 88 (27.8) 89 (28.1) 52 (16.4)  
Ferritin No METS 286 (26.4) 262 (24.2) 266 (24.5) 270 (24.9) 0.03 
 Incident METS 66 (20.8) 70 (22.1) 77 (24.3) 104 (32.8)  
Transferrin No METS 285 (26.3) 268 (24.7) 265 (24.5) 266 (24.5) 0.03 
 Incident METS 60 (19.0) 82 (26.0) 76 (24.1) 98 (31.0)  
Women       
Iron No METS 396 (25.4) 416 (26.6) 423 (27.1) 327 (20.9) 0.006 
 Incident METS 100 (32.5) 83 (27.0) 84 (27.3) 41 (13.3)  
Ferritin No METS 416 (26.6) 378 (24.2) 403 (25.8) 365 (23.4) 0.03 
 Incident METS 71 (23.1) 70 (22.7) 70 (22.7) 97 (31.5)  
Transferrin  No METS 390 (25.0) 377 (24.2) 394 (25.3) 397 (25.5) 0.04 
 Incident METS 55 (17.9) 88 (28.7) 78 (25.4) 86 (28.0)  
 
Results are expressed as number of participants and (percentage). METS, metabolic syndrome. Statistical analysis by chi-square. 
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Table 2: Multivariate analysis of the association between quartiles of markers of iron metabolism and incident metabolic syndrome, stratified by 
gender, CoLaus study. 
 First Second Third Fourth p-value § p-value §§ 
Men       
Iron 1 (ref.) 0.91 (0.62 - 1.31) 0.92 (0.63 - 1.33) 0.81 (0.53 - 1.24) 0.36 0.33 
Ferritin 1 (ref.) 1.18 (0.78 - 1.78) 1.16 (0.77 - 1.73) 1.30 (0.88 - 1.92) 0.22 0.18 
Transferrin  1 (ref.) 1.40 (0.93 - 2.11) 1.38 (0.92 - 2.08) 1.55 (1.04 - 2.31) 0.04 0.03 
Women       
Iron 1 (ref.) 0.72 (0.50 - 1.04) 0.83 (0.58 - 1.19) 0.51 (0.33 - 0.80) 0.008 0.003 
Ferritin 1 (ref.) 1.00 (0.68 - 1.50) 0.82 (0.55 - 1.22) 1.11 (0.76 - 1.63) 0.85 0.58 
Transferrin  1 (ref.) 1.77 (1.18 - 2.65) 1.44 (0.96 - 2.18) 1.45 (0.97 - 2.17) 0.16 0.07 
Results are expressed as Odds ratio for metabolic syndrome and (95% confidence interval). Statistical analysis by logistic regression adjusting for 
age, body mass index categories (normal, overweight, obese), smoking (never, former, current), alcohol consumption (none, 1-13 and ≥14 
drinks/week), iron supplement use (yes/no), CRP levels (log-transformed) and altered hepatic markers (yes/no). For women, a further 
adjustment on hormonal treatment (contraception of hormone replacement treatment for postmenopausal women) was also applied. *, also 
adjusting for gender and menopausal status; §, test for trend using all quartiles; §§, test comparing the last to the first quartile. 
Iron 0.85 [0.56 - 1.30] 0.46
Ferritin 1.26 [0.85 - 1.87] 0.24
Transferrin 1.51 [1.01 - 2.24] 0.04
CTF 1.51 [1.01 - 2.24] 0.04
Saturation 1.04 [0.69 - 1.56] 0.86
Men, incidence of MS
Expressed as Odds-ratio and [95% CI] for the 4th quartile relative to the first.
Iron 0.43 [0.20 - 0.94] 0.04
Ferritin 0.76 [0.39 - 1.47] 0.42
Transferrin 1.34 [0.64 - 2.79] 0.77
CTF 1.34 [0.64 - 2.79] 0.77
Saturation 0.58 [0.27 - 1.22] 0.15
Women pre, incidence of MS
Expressed as Odds-ratio and [95% CI] for the 4th quartile relative to the first.
Iron 0.63 [0.37 - 1.07] 0.09
Ferritin 1.55 [0.96 - 2.50] 0.08
Transferrin 1.66 [1.01 - 2.74] 0.05
CTF 1.66 [1.01 - 2.74] 0.05
Saturation 0.68 [0.41 - 1.14] 0.15
Women post, incidence of MS
Expressed as Odds-ratio and [95% CI] for the 4th quartile relative to the first.
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Supplementary table 1: clinical characteristics at baseline of the participants, stratified by gender and 
menopausal status (women). 
 Men Women, 
premenopausal 
Women, 
postmenopausal 
Sample size 1,401 943 927 
Age (years) 50.1 ± 10.3 44.0 ± 5.5 60.5 ± 7.0 
BMI (kg/m2) 25.3 ± 3.0 23.5 ± 3.7 24.3 ± 3.7 
BMI categories (%)    
Normal 683 (48.8) 675 (71.6) 589 (63.5) 
Overweight 627 (44.8) 214 (22.7) 274 (29.6) 
Obese 91 (6.5) 54 (5.7) 64 (6.9) 
Waist (cm) 92.0 ± 8.6 78.1 ± 9.0 81.8 ± 10.0 
Abdominal obesity (%) 143 (10.2) 136 (14.4) 239 (25.8) 
Smoking categories (%)    
Never 533 (38.0) 404 (42.8) 455 (49.1) 
Former 501 (35.8) 265 (28.1) 291 (31.4) 
Current 367 (26.2) 274 (29.1) 181 (19.5) 
Alcohol consumption (%)    
None 205 (14.6) 309 (32.8) 319 (34.4) 
1-13 / week 809 (57.7) 580 (61.5) 542 (58.5) 
14+ / week 387 (27.6) 54 (5.7) 66 (7.1) 
Iron supplementation (%) 5 (0.4) 48 (5.1) 14 (1.5) 
CRP (mg/L) 1.81 ± 2.68 2.19 ± 3.42 2.34 ± 3.2 
Altered hepatic markers (%) 30 (2.1) 5 (0.5) 15 (1.6) 
Hormonal treatment (%) - 172 (18.2) 585 (63.1) 
HDL cholesterol (mmol/L) 1.51 ± 0.35 1.83 ± 0.39 1.93 ± 0.41 
Triglycerides (mmol/L) 1.30 ± 0.88 0.95 ± 0.45 1.05 ± 0.45 
Glycaemia (mmol/L) 5.48 ± 0.80 5.09 ± 0.49 5.23 ± 0.61 
SBP (mm Hg) 128 ± 15 116 ± 13 127 ± 18 
DBP (mm Hg) 79 ± 10 75 ± 10 77 ± 10 
Iron (µg/dL) 99 ± 29 94 ± 34 95 ± 28 
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Ferritin (µg/L) 230 ± 154 67 ± 57 122 ± 82 
Transferrin (mg/dL) 232 ± 33 247 ± 43 233 ± 33 
 
Results are expressed as mean ± standard deviation or number of participants (percentage). BMI, body 
mass index; HDL, high density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
CRP; C-reactive protein. 
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Supplementary table 2: Association between quartiles of markers of iron metabolism and incident metabolic syndrome, women only, stratified 
by menopausal status, CoLaus study. 
  First Second Third Fourth p-value 
Women, premenopausal       
Iron No METS 217 (25.5) 222 (26.1) 240 (28.2) 171 (20.1) 0.10 
 Incident METS 32 (34.4) 25 (26.9) 26 (28.0) 10 (10.8)  
Ferritin No METS 222 (26.1) 203 (23.9) 214 (25.2) 211 (24.8) 0.99 
 Incident METS 24 (25.8) 22 (23.7) 24 (25.8) 23 (24.7)  
Transferrin No METS 208 (24.5) 208 (24.5) 213 (25.1) 219 (25.8) 0.17 
 Incident METS 14 (15.1) 29 (31.2) 23 (24.7) 27 (29.0)  
Women, postmenopausal       
Iron No METS 179 (25.1) 194 (27.3) 183 (25.7) 156 (21.9) 0.06 
 Incident METS 68 (31.6) 58 (27.0) 58 (27.0) 31 (14.4)  
Ferritin No METS 194 (27.3) 175 (24.6) 189 (26.5) 154 (21.6) 0.002 
 Incident METS 47 (21.9) 48 (22.3) 46 (21.4) 74 (34.4)  
Transferrin No METS 182 (25.6) 169 (23.8) 181 (25.5) 178 (25.1) 0.24 
 Incident METS 41 (19.2) 59 (27.6) 55 (25.7) 59 (27.6)  
 
Results are expressed as number of participants and (percentage). METS, metabolic syndrome. Statistical analysis by chi-square. 
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Supplementary table 3: Multivariate analysis of the association between quartiles of markers of iron metabolism and incident metabolic 
syndrome, women only, stratified by menopausal status, CoLaus study. 
 First Second Third Fourth p-value § p-value §§ 
Women, premenopausal       
Iron 1 (ref.) 0.59 (0.32 - 1.09) 0.70 (0.38 - 1.28) 0.44 (0.20 - 0.99) 0.08 0.05 
Ferritin 1 (ref.) 1.11 (0.57 - 2.16) 0.82 (0.42 - 1.57) 0.67 (0.34 - 1.33) 0.17 0.25 
Transferrin  1 (ref.) 1.79 (0.87 - 3.69) 1.45 (0.69 - 3.06) 1.54 (0.72 - 3.29) 0.38 0.27 
Women, postmenopausal       
Iron 1 (ref.) 0.80 (0.51 - 1.25) 0.92 (0.58 - 1.45) 0.59 (0.35 - 1.00) 0.09 0.052 
Ferritin 1 (ref.) 1.02 (0.62 - 1.68) 0.85 (0.51 - 1.40) 1.49 (0.93 - 2.38) 0.19 0.10 
Transferrin 1 (ref.) 1.81 (1.10 - 2.98) 1.54 (0.93 - 2.56) 1.63 (1.00 - 2.67) 0.10 0.052 
Results are expressed as Odds ratio for metabolic syndrome and (95% confidence interval). Statistical analysis by logistic regression adjusting for 
age, body mass index categories (normal, overweight, obese), smoking (never, former, current), alcohol consumption (none, 1-13 and ≥14 
drinks/week), iron supplement use (yes/no), CRP levels (log-transformed), hormonal treatment (contraception of hormone replacement 
treatment for postmenopausal women) and altered hepatic markers (yes/no). §, test for trend using all quartiles; §§, test comparing the last to 
the first quartile.  
 
